Cenduit to Lead Panel at 2015 Interactive Response Technologies in Clinical Trials Forum in Philadelphia

RALEIGH, NC, UNITED STATES - Oct 20, 2015 - Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, is showcasing its solutions and expertise as the largest interactive response technology (IRT) specialist in the world by leading a panel at CBI’s 2015 Interactive Response Technologies in Clinical Trials Forum. The panel, titled “Build Electronic Drug Accountability into IRT,” will feature four IRT experts, including Cenduit Senior Project Manager Carly Newhardt.

 

“The pharmaceutical industry has gradually accepted electronic drug accountability over the past several years,” said Newhardt. “We look forward to discussing all aspects of electronic drug accountability, highlighting its integration into IRT systems and the challenges and successes it has faced in the industry.”

 

The panel discussion will focus on industry uptake of electronic drug accountability, the transfer from paper to electronic processes, the impact on patient compliance and more. Representatives from Bristol-Myers Squibb, Fisher Clinical Services and Biogen will also be presenting during the panel.

 

Attendees are invited to stop by the Cenduit booth to learn how the company’s IRT solutions can help sponsors increase efficiencies and reduce costs to get their product to market faster. 

 

WHO: Experts speaking at the Build Electronic Drug Accountability into IRT panel:

  • Moderator - Doug Meyer, Associate Director, Clinical Drug Supply, Biogen
  • Carly Newhardt, Senior Project Manager at Cenduit
  • Craig Mooney, Director of IRT Services at Bristol-Myers Squibb
  • Mohamed Rajmohamed, Manager of Returns, Reconciliation, & Destruction at Fisher Clinical Services

 

WHEN:  October 26-27, 2015

 

WHERE:   Hilton Philadelphia at Penn’s Landing
               201 S Christopher Columbus Blvd
               Philadelphia, PA 19106

 

DETAILS:  For media inquiries, please contact Bernadette Miller at Largemouth Communications, (703) 297-5992, bernadette@largemouthpr.com.

 

ABOUT:  Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration.  Cenduit has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For additional information, visit Cenduit online at www.cenduit.com; on Twitter @CenduitLLC or on LinkedIn at www.LinkedIn.com/Company/Cenduit.

 

 

                                                            ###